This contrasts with MET mutations identified in non‐small‐cell lung cancer (NSCLC), which lead to exon 14 skipping and deletion of a regulatory domain: In this latter case, the mutated receptor still requires ligand stimulation. Here, MET is linked to non-small cell lung carcinoma.